知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

27 records (took 0.071 seconds)

    Method of treatment of myocardial infarction
    17.
    发明申请
    Method of treatment of myocardial infarction 审中-公开
    心肌梗死的治疗方法

    公开(公告)号：US20080200481A1

    公开(公告)日：2008-08-21

    申请号：US12148001

    申请日：2008-04-16

    Applicant: David A. Cheresh ,  Robert Paul ,  Brian Eliceiri

    Inventor： David A. Cheresh ,  Robert Paul ,  Brian Eliceiri

    IPC: A61K31/519 ,  A61P9/10

    CPC classification number: A61K31/519 ,  A01K67/0271 ,  A61K38/45 ,  A61K48/00

    Abstract: Myocardial infarction in a mammal is treated by administering to the mammal a therapeutically effective amount of a chemical Src family tyrosine kinase protein inhibitor and the use of such inhibitor compounds for the preparation of a medicament for treating myocardial infarction. Myocardial infarction can be prevented by administering to the mammal a prophylactic amount of the inhibitor. The inhibitor preferably is an inhibitor of Src protein selected from the group consisting of a pyrazolopyrimidine class Src family tyrosine kinase inhibitor, a macrocyclic dienone class Src family tyrosine kinase inhibitor, a pyrido[2,3-d]pyrimidine class Src family tyrosine kinase inhibitor, a 4-anilino-3-quinolinecarbonitrile class Src family tyrosine kinase inhibitor, and a mixture thereof. The Src family tyrosine kinase inhibitors can be used to prepare medicaments for the treatment of myocardial infarction. Also disclosed are articles of manufacture containing a chemical Src family tyrosine kinase inhibitor.

    Abstract translation: 通过向哺乳动物施用治疗有效量的化学品Src家族酪氨酸激酶蛋白抑制剂和这种抑制剂化合物用于制备用于治疗心肌梗塞的药物的用途来治疗哺乳动物的心肌梗死。 可以通过向哺乳动物施用预防量的抑制剂来防止心肌梗死。 抑制剂优选是Src蛋白的抑制剂，其选自吡唑并嘧啶类Src家族酪氨酸激酶抑制剂，大环二烯酮类Src家族酪氨酸激酶抑制剂，吡啶并[2,3-d]嘧啶类Src家族酪氨酸激酶抑制剂 ，4-苯胺基-3-喹啉甲腈类Src家族酪氨酸激酶抑制剂及其混合物。 Src家族酪氨酸激酶抑制剂可用于制备用于治疗心肌梗死的药物。 还公开了含有化学Src家族酪氨酸激酶抑制剂的制品。

    Peptide-based angiogenesis inhibitors and methods of use thereof
    19.
    发明授权
    Peptide-based angiogenesis inhibitors and methods of use thereof 有权
    基于肽的血管生成抑制剂及其使用方法

    公开(公告)号：US07125849B2

    公开(公告)日：2006-10-24

    申请号：US10341815

    申请日：2003-01-14

    Applicant: David A. Cheresh ,  John Hood ,  Martin A. Schwartz ,  William B. Kiosses

    Inventor： David A. Cheresh ,  John Hood ,  Martin A. Schwartz ,  William B. Kiosses

    IPC: A61K38/10 ,  A61K38/08 ,  C07K7/08

    CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K7/08

    Abstract: Angiogenesis inhibitors and methods of use thereof are disclosed. The inhibitors are substantially pure oligopeptides consisting essentially of 7–20 amino acid residues and comprising a proline-rich sequence of five amino acid residues PPXPP, SEQ ID NO: 1, wherein X is an amino acid residue selected from the group consisting of alanine, glycine, serine, threonine, valine, leucine and methionine. In a preferred embodiment, the proline-rich polypeptide is covalently bound to a transport molecule such as a Tat-derived transport polypeptide.

    Abstract translation: 公开了血管发生抑制剂及其使用方法。 抑制剂是基本上由7-20个氨基酸残基组成的基本上纯的寡肽，包含富含5个氨基酸残基PPXPP，SEQ ID NO：1的富含脯氨酸的序列，其中X是选自丙氨酸， 甘氨酸，丝氨酸，苏氨酸，缬氨酸，亮氨酸和甲硫氨酸。 在优选的实施方案中，富含脯氨酸的多肽与转运分子如Tat衍生的转运多肽共价结合。

Patent Agency Ranking